COMPLICATIONS ASSOCIATED WITH RENAL ARTERY ACCESS IN PERCUTANEOUS INTERVENTIONS

Prepared by **Dr. Sidhartha Mullapudi**, DrNB (Cardiology), MD (General Medicine)
Last reviewed: October 2026

I DEFINITION AND RESTRICTED CLINICAL INDICATIONS (ESC 2024 PAAD / ACC-AHA)

- **Definition:** Percutaneous Transluminal Renal Angioplasty (PTRA) with or without stenting involves selective catheterization of the renal arteries to treat hemodynamically significant **Renal Artery Stenosis (RAS)** caused by **atherosclerosis (90 percent — typically ostial/proximal 1 cm)** or **Fibromuscular Dysplasia (FMD, 10 percent — typically mid-to-distal main renal artery "string-of-beads" in young women)** (plus **Takayasu Arteritis** in India).
- **Why Complication Prevention is Paramount (The Post-ASTRAL & CORAL Era):** Because landmark randomized trials (**ASTRAL [2009] and CORAL [2014]**) proved that **routine renal artery stenting does NOT reduce cardiovascular or renal events over optimal medical therapy in unselected atherosclerotic RAS** (**ESC 2024 Class III for routine stenting in unilateral atherosclerotic RAS**), invasive renal intervention is restricted strictly to high-yield clinical phenotypes where procedural complications must be kept near zero:
- **Fibromuscular Dysplasia (FMD) with Hypertension: Plain Balloon Angioplasty WITHOUT stenting is Class IIa** (stenting is reserved strictly for bailout dissection/rupture).
- **High-Risk Atherosclerotic RAS (Class IIb Consideration):** Recurrent unexplained **"Flash" Pulmonary Edema (Pickering Syndrome)**, refractory acute decompensated heart failure, **oligo-anuric AKI after starting ACEi/ARB in bilateral RAS or solitary functioning kidney**, or rapid progressive CKD with bilateral >70–80% stenosis.

II TARGET VESSEL (RENAL OSTIUM AND PARENCHYMAL) COMPLICATIONS

- **Ostial and Main Renal Artery Dissection (1% to 5%):**
  - **Mechanism:** Aggressive deep-seating ("jack-hammering") of a non-coaxial guiding catheter against a calcified aorto-ostial plaque, forceful contrast injection against a **damped/ventricularized pressure waveform** (hydraulic dissection), or subintimal guidewire passage.
  - **Clinical Consequence and Bailout:** Flow-limiting spiral dissection causes **acute renal artery thrombosis and segmental/global renal infarction** (flank pain, hematuria, LDH spike, acute anuria); treated immediately by maintaining true-lumen wire position and deploying a **balloon-expandable bare-metal or drug-eluting stent** across the dissection entry tear.
  - **Renal Artery Perforation or Rupture (<1% — Catastrophic Emergency):**
  - **Mechanism:** Oversizing the angioplasty balloon or stent (**balloon-to-artery ratio >1.1:1**) or high-pressure inflation across a heavily calcified, eccentric, or fibrotic (Takayasu) stenosis.
  - **Clinical Consequence and Bailout:** Rapid, life-threatening **retroperitoneal hemorrhage** and hemorrhagic shock (sudden flank/back pain, hypotension, tachycardia, loss of renal silhouette on fluoroscopy). **Immediate Bailout Protocol:** (1) **Inflate a compliant balloon across the perforation site** at low pressure for immediate hemostatic tamponade (never pull the guidewire!); (2) Reverse heparin only after covered stent preparation if needed; and (3) Deploy a **PTFE-Covered Stent (e.g., GraftMaster, PK Papyrus, Viabahn, or BeGraft)** using a "ping-pong" dual-guide or single large-guide technique.
  - **Distal Atheroembolization (Cholesterol Crystal Embolization Syndrome — 2% to 8%):**
  - **Mechanism:** Scraping friable, ulcerated **juxtarenal abdominal aortic atheroma ("shaggy aorta")** or ostial renal plaque during catheter engagement and stent expansion showers microscopic **cholesterol crystals** into the distal arcuate/interlobular renal arterioles, mesenteric bed, and lower extremities.
  - **Clinical Presentation and Hallmarks:** Unlike Contrast-Associated AKI (which peaks at 48–72 hours and recovers within 7–10 days), **Cholesterol Emboli Syndrome presents subacutely 1 to 4 weeks post-procedure with progressive, often irreversible renal failure**, accompanied by **"Blue Toe Syndrome"** (painful cyanotic toes with intact pedal pulses), **livedo reticularis** of the legs/abdomen, **Hollenhorst plaques**, **peripheral blood eosinophilia (70–80%), eosinophiluria, hypocomplementemia (low C3/C4)**, and **biconvex needle-shaped "cholesterol clefts"** on skin/renal biopsy.
  - **Prevention:** Use the **"No-Touch" Technique** (placing a 0.014" or 0.035" buddy wire in the aorta to keep the guide catheter tip slightly off the aortic wall during cannulation) or **telescoping catheter-in-catheter ("mother-and-child") delivery**.
  - **Hydrophilic Guidewire Perforation of the Renal Parenchyma (Subcapsular Renal Hematoma):**
  - **Mechanism:** Allowing the tip of a stiff or **hydrophilic (polymer-jacketed) 0.014-inch guidewire** to migrate distally into a tiny cortical branch during balloon/stent exchanges, perforating the renal cortex and causing a **subcapsular or perinephric hematoma** (**Page Kidney** -> severe renin-mediated hypertension and flank pain).
  - **Management:** Prevented by keeping the non-hydrophilic workhorse wire tip parked visibly in a main segmental branch; if active cortical bleeding occurs, perform **super-selective microcatheter coil or gelfoam embolization** of the bleeding tertiary branch.

Complication Category	Specific Complication	Primary Mechanism / Trigger	Definitive Prevention & Bailout Strategy
Target Vessel Mechanical	**Renal Artery Perforation / Rupture**	Balloon/stent oversizing (>1:1) in heavy calcium	**Immediate low-pressure balloon tamponade** -> deploy **PTFE-Covered Stent**
Target Vessel Mechanical	**Ostial / Spiral Dissection**	Non-coaxial guide trauma; injecting on a **damped pressure waveform**	Never inject on damped waveform; bailout **balloon-expandable ostial stent**
Parenchymal Wire Injury	**Subcapsular Hematoma (Page Kidney)**	Distal migration of **hydrophilic wire tip** into cortical perforators	Keep non-hydrophilic wire tip in main segmental branch; **microcoil embolization** if bleeding
Microvascular Embolic	**Cholesterol Emboli Syndrome**	Scraping shaggy juxtarenal aorta -> subacute CKD at 1–4 wk + **Blue Toes + Eosinophilia**	**"No-Touch" / telescoping guide technique**; high-intensity statin
Metabolic / Systemic	**Contrast-Associated AKI (CA-AKI)**	Medullary hypoxia & tubular toxicity (peaks 48–72 h, recovers in 7–10 d)	**LVEDP-guided isotonic 0.9% NaCl hydration (POSEIDON)** + **CV/eGFR ratio < 2–3** + **CO2 / IVUS**

III ACCESS-SITE COMPLICATIONS (FEMORAL VS. TRANSRADIAL / BRACHIAL)

- **Femoral Arterial Access:**
  - **Risks:** Because patients with atherosclerotic RAS have a high prevalence of concomitant **aorto-iliac occlusive disease** and calcified femoral arteries, femoral access carries increased risks of **retroperitoneal hemorrhage** (puncture above the inguinal ligament / inferior epigastric artery), **pseudoaneurysm, arteriovenous fistula, and acute limb ischemia**.
  - **Transradial or Brachial Access:**
  - **Anatomical Advantage vs. Neurological Hazard:** Because the native renal arteries often angle **caudally (downward)** off the abdominal aorta, a cranial **"top-down" left/right radial (using long 110–125 cm sheaths/catheters) or brachial approach** provides coaxial alignment and eliminates femoral bleeding (**MATRIX Trial**). However, navigating large sheaths across a diseased aortic arch carries a small (~0.5–1.0%) risk of **cerebral atheroembolization (stroke)**, and high brachial punctures carry a risk of **median nerve compression** from compartment hematoma.

IV CONTRAST-ASSOCIATED ACUTE KIDNEY INJURY (CA-AKI) AND SYSTEMIC BEST PRACTICES

- **Pre-Procedural Risk Scoring and Evidence-Based Hydration:**
  - **Risk Stratification:** Calculate the **Mehran CA-AKI Score** and **CRUSADE / ARC-HBR Bleeding Score**.
  - **Isotonic Crystalloid Hydration (PRESERVE & POSEIDON Trials — Class I):** Administer **Intravenous 0.9% Isotonic Normal Saline** (1.0 to 1.5 mL/kg/h for 3 to 12 hours pre-procedure and 6 to 24 hours post-procedure, adjusted via the **POSEIDON LVEDP-guided protocol**: 5 mL/kg/h for LVEDP <13 mmHg, 3 mL/kg/h for LVEDP 13–18 mmHg, and 1.5 mL/kg/h for LVEDP >18 mmHg, which reduced CA-AKI by **59 percent**).
  - **What NOT to Give (PRESERVE Trial, *NEJM* 2018 — Class III No Benefit):** The 2x2 factorial **PRESERVE Trial** (n = 5,177) definitively proved that **Intravenous Sodium Bicarbonate is NOT superior to Normal Saline** and **Oral N-Acetylcysteine (NAC) provides ZERO benefit** for preventing CA-AKI, dialysis, or death.
  - **Intra-Procedural Best Practices ("Zero-Complication Execution"):**
  - **Ultrasound-Guided Micropuncture Access:** Real-time ultrasound guidance ensures anterior single-wall common femoral puncture over the femoral head (below the inferior epigastric artery and above the femoral bifurcation) or clean radial access.
  - **Strict Contrast Volume Ceiling (CV / eGFR Ratio < 2.0 to 3.0):** Total iso-osmolar or low-osmolar iodinated contrast volume (in mL) must be kept **strictly below 2 to 3 times the patient's eGFR**; in severe CKD (eGFR <30 mL/min), **Intravascular Ultrasound (IVUS)** or **Carbon Dioxide (CO2) digital subtraction angiography** (safe below the diaphragm) enables **"Zero- or Ultra-Low-Contrast" renal stenting**.
  - **Waveform Vigilance and ACT Control:** Never inject contrast when the arterial tip pressure waveform is **damped or ventricularized**; maintain **Activated Clotting Time (ACT) at 250 to 300 seconds** with unfractionated heparin.

KEY REFERENCES

- **Cooper CJ, Murphy TP, Cutlip DE, et al. (CORAL Investigators):** Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis, *New England Journal of Medicine*, 2014.
- **ASTRAL Investigators (Wheatley K, Ives N, Gray R, et al.):** Revascularization versus Medical Therapy for Renal-Artery Stenosis, *New England Journal of Medicine*, 2009.
- **Weisbord SD, Gallagher M, Jneid H, et al. (PRESERVE Trial Investigators):** Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine, *New England Journal of Medicine*, 2018.
- **Brar SS, Aharonian V, Mansukhani P, et al. (POSEIDON Investigators):** Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial, *The Lancet*, 2014.